Arcoxia licensed for pain following dental surgery

on the 3 September 2012

Arcoxia (etoricoxib) has been approved for the short-term treatment of moderate pain associated with dental surgery.

As well as it's use following dental surgery, etoricoxib is also licensed for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis | SCIENCE PHOTO LIBRARY
As well as it's use following dental surgery, etoricoxib is also licensed for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis | SCIENCE PHOTO LIBRARY

The recommended dose of etoricoxib is 90mg once daily for a maximum of 3 days. Additional postoperative analgesia can be prescribed if required.

No dosage adjustment is necessary for the elderly. However, etoricoxib is contraindicated in patients with creatinine clearance <30ml/min and dose reduction is required for patients with hepatic impairment.

View Arcoxia drug record

Further information: Merck Sharp & Dohme Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more